Novel Scaffold Fingerprint (SFP): Applications in Scaffold Hopping and Scaffold-Based Selection of Diverse Compounds

A novel 2D Scaffold FingerPrint (SFP) for mining ring fragments is presented. The rings are described not only by their topology, shape, and pharmacophoric features (hydrogen-bond acceptors and donors, their relative locations, sp3 carbons, and chirality) but also by the position and nature of their growing vectors because they play a critical role from the drug discovery perspective. SFP can be used (i) to identify alternative chemotypes to a reference ring either in a visual mode or by running quantitative similarity searches and (ii) in chemotype-based diversity selections. Two retrospective case studies focused on melanin concentrating hormone 1-receptor antagonists (MCH-R1) and phosphodiesterase-5 inhibitors (PDE5) demonstrate the capability of this method for identifying novel structurally different and synthetically accessible chemotypes. Good enrichment factor (155 and 219) and recall values (46% and 73%) are found within the first 100 ranked hits (0.3% of screened database). Our 2D SFP descriptor outperforms well-validated current gold-standard 2D fingerprints (ECFP_6) and 3D approaches based on shape and electrostatic similarity. Scaffold-based selection of diverse compounds has a critical impact on corporate library design and compound acquisitions; thus, a novel strategy is introduced that uses diverse scaffold selections using this SFP descriptor combined with R-group selection at the different substitution sites. Both approaches are available as part of an interactive web-based application that requires minimal input and no computational knowledge by medicinal chemists.

[1]  Peter Ertl,et al.  Intuitive Ordering of Scaffolds and Scaffold Similarity Searching Using Scaffold Keys , 2014, J. Chem. Inf. Model..

[2]  Obdulia Rabal,et al.  Using Novel Descriptor Accounting for Ligand-Receptor Interactions To Define and Visually Explore Biologically Relevant Chemical Space , 2012, J. Chem. Inf. Model..

[3]  Howard Miller,et al.  Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors. , 2013, Bioorganic & medicinal chemistry letters.

[4]  Obdulia Rabal,et al.  Fragment-Hopping-Based Discovery of a Novel Chemical Series of Proto-Oncogene PIM-1 Kinase Inhibitors , 2012, PloS one.

[5]  Benjamin A. Ellingson,et al.  Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database , 2010, J. Chem. Inf. Model..

[6]  Tudor I. Oprea,et al.  Scaffold Topologies. 2. Analysis of Chemical Databases , 2008, J. Chem. Inf. Model..

[7]  Sarah R. Langdon,et al.  Scaffold Diversity of Exemplified Medicinal Chemistry Space , 2011, J. Chem. Inf. Model..

[8]  Alan H. Lipkus,et al.  Exploring Chemical Rings in a Simple Topological-Descriptor Space , 2001, J. Chem. Inf. Comput. Sci..

[9]  Andreas Bender,et al.  “Plate Cherry Picking”: A Novel Semi-Sequential Screening Paradigm for Cheaper, Faster, Information-Rich Compound Selection , 2007, Journal of biomolecular screening.

[10]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[11]  Anders Wallqvist,et al.  Classification of scaffold-hopping approaches. , 2012, Drug discovery today.

[12]  O. Rabal,et al.  Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach. , 2010, Journal of medicinal chemistry.

[13]  David Messersmith,et al.  Inhibiteurs de la phosphatidylinositol 3-kinase à base de tétrahydrothiazolopyridine , 2010 .

[14]  Markus Wagener,et al.  The Quest for Bioisosteric Replacements , 2006, J. Chem. Inf. Model..

[15]  Thierry Kogej,et al.  Scaffold Hopping by Fragment Replacement , 2013, J. Chem. Inf. Model..

[16]  Christos A. Nicolaou,et al.  Analysis of Large Screening Data Sets via Adaptively Grown Phylogenetic-Like Trees , 2002, J. Chem. Inf. Comput. Sci..

[17]  Thomas Lampe,et al.  Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[18]  Ian A. Watson,et al.  Selection of heterocycles for drug design. , 2004, Journal of molecular graphics & modelling.

[19]  P. Hawkins,et al.  Comparison of shape-matching and docking as virtual screening tools. , 2007, Journal of medicinal chemistry.

[20]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[21]  Gary Walker,et al.  Enhancing Hit Quality and Diversity within Assay Throughput Constraints , 2005 .

[22]  E. Casale,et al.  Through the "gatekeeper door": exploiting the active kinase conformation. , 2010, Journal of medicinal chemistry.

[23]  M. J. Bishop,et al.  The discovery and optimization of pyrimidinone-containing MCH R1 antagonists. , 2006, Bioorganic & medicinal chemistry letters.

[24]  Tudor I. Oprea,et al.  Scaffold Topologies. 1. Exhaustive Enumeration up to Eight Rings , 2008, J. Chem. Inf. Model..

[25]  Anastasia Diamantopoulou,et al.  Effects of an Early Experience Involving Training in a T-Maze Under either Denial or Receipt of Expected Reward through Maternal Contact , 2013, Front. Endocrinol..

[26]  Gavin Harper,et al.  Drug rings database with web interface. A tool for identifying alternative chemical rings in lead discovery programs. , 2003, Journal of medicinal chemistry.

[27]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[28]  Peter Ertl,et al.  Database of bioactive ring systems with calculated properties and its use in bioisosteric design and scaffold hopping. , 2012, Bioorganic & medicinal chemistry.

[29]  Brajesh K. Rai,et al.  Exploring Aromatic Chemical Space with NEAT: Novel and Electronically Equivalent Aromatic Template , 2012, J. Chem. Inf. Model..

[30]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[31]  Richard D. Taylor,et al.  Rings in drugs. , 2014, Journal of medicinal chemistry.

[32]  Douglas J. MacNeil,et al.  The Role of Melanin-Concentrating Hormone and Its Receptors in Energy Homeostasis , 2013, Front. Endocrinol..

[33]  José L. Medina-Franco,et al.  Scaffold Diversity Analysis of Compound Data Sets Using an Entropy-Based Measure , 2009 .

[34]  Ellen R. Laird,et al.  Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships. , 2011, Bioorganic & medicinal chemistry letters.

[35]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[36]  Ola Engkvist,et al.  Molecular Topology Analysis of the Differences between Drugs, Clinical Candidate Compounds, and Bioactive Molecules , 2010, J. Chem. Inf. Model..

[37]  Brian K. Shoichet,et al.  Increasing Chemical Space Coverage by Combining Empirical and Computational Fragment Screens , 2014, ACS chemical biology.

[38]  Peter Ertl,et al.  Quest for the rings. In silico exploration of ring universe to identify novel bioactive heteroaromatic scaffolds. , 2006, Journal of medicinal chemistry.

[39]  Yong-Jin Xu,et al.  Using Molecular Equivalence Numbers to Visually Explore Structural Features that Distinguish Chemical Libraries. , 2002 .

[40]  Ramaswamy Nilakantan,et al.  A Ring-Based Chemical Structural Query System: Use of a Novel Ring-Complexity Heuristic. , 1990 .

[41]  Anders Johansson,et al.  Recent progress in the discovery of melanin-concentrating hormone 1-receptor antagonists , 2011, Expert opinion on therapeutic patents.

[42]  Obdulia Rabal,et al.  Biologically Relevant Chemical Space Navigator: From Patent and Structure-Activity Relationship Analysis to Library Acquisition and Design , 2012, J. Chem. Inf. Model..

[43]  Anang A Shelat,et al.  Scaffold composition and biological relevance of screening libraries. , 2007, Nature chemical biology.

[44]  Yong-Jin Xu,et al.  Algorithm for Naming Molecular Equivalence Classes Represented by Labeled Pseudographs. , 2001 .

[45]  Stefan Wetzel,et al.  Natural-product-derived fragments for fragment-based ligand discovery , 2012, Nature Chemistry.

[46]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[47]  Schmid,et al.  "Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. , 1999, Angewandte Chemie.

[48]  Julen Oyarzabal,et al.  Novel approach for chemotype hopping based on annotated databases of chemically feasible fragments and a prospective case study: new melanin concentrating hormone antagonists. , 2009, Journal of medicinal chemistry.

[49]  Anthony Nicholls,et al.  Conformer Generation with OMEGA: Learning from the Data Set and the Analysis of Failures , 2012, J. Chem. Inf. Model..

[50]  Calvin Yu-Chian Chen,et al.  TCM Database@Taiwan: The World's Largest Traditional Chinese Medicine Database for Drug Screening In Silico , 2011, PloS one.

[51]  W. Pitt,et al.  Heteroaromatic rings of the future. , 2009, Journal of medicinal chemistry.